started · updated
Warp Sciences launches with $215M to automate drug discovery
Warp Sciences, led by former OpenAI science chief Kevin Weil, has launched with $215 million in funding to develop AI-driven robotic laboratories for drug discovery chemistry. The company aims to provide biotech and pharmaceutical firms with lead optimization analog synthesis services within the United States.
By utilizing robots that learn tasks from chemists via cameras and sensor gloves, Warp intends to accelerate the process of refining drug molecules. The company seeks to address the bottleneck where AI-driven molecular suggestions outpace the speed of manual laboratory testing. Data generated from these physical experiments will be used to train Warp’s proprietary AI models.
Co-founder and Chief Scientific Officer Sol Reisberg noted that the move toward U.S.-based contract research is intended to protect intellectual property. Currently, a significant portion of outsourced chemistry work is performed offshore, particularly in China. Warp aims to provide high-caliber domestic services at competitive prices compared to overseas partners.
Entities
Biotechnology Innovation Organization · Kevin Weil · OpenAI · Sol Reisberg · Warp Sciences